QBW251
Total Payments
$3.6M
Transactions
173
Doctors
18
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.4M | 44 | 0 |
| 2019 | $411,162 | 114 | 18 |
| 2018 | $15,707 | 4 | 0 |
| 2017 | $828,327 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 96 | 99.7% |
| Travel and Lodging | $5,780 | 33 | 0.2% |
| Food and Beverage | $4,237 | 44 | 0.1% |
Payments by Type
Research
$3.6M
96 transactions
General
$10,018
77 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 24 WEEK MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL QBW251 IN COPD PATIENTS ON TRIPLE THERAPY (LABA/LAMA/ICS) | Novartis Pharmaceuticals Corporation | $2.8M | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MULTIPLE DOSES OF QBW251 IN PATIENTS WITH COPD | Novartis Pharmaceuticals Corporation | $830,232 | 0 |
| A 24 WEEK MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL QBW251 IN COPD PATIENTS ON TRIPLE THERAPY (LABA/LAMA/ICS) | NOVARTIS PHARMACEUTICALS CORPORATION | $14,612 | 0 |
| A RANDOMIZED PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY PHARMACODYNAMICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF QBW251 IN HEALTHY SUBJECTS AND CYSTIC FIBROSIS PATIENTS | Novartis Pharmaceuticals Corporation | $13,802 | 0 |
Top Doctors Receiving Payments for QBW251
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Shelby, NC | $3.6M | 93 |
| , MD | Allergy | Los Angeles, CA | $997.47 | 6 |
| , MD | Pulmonary Disease | Westminster, CA | $921.93 | 6 |
| , MD | Pulmonary Disease | Lynbrook, NY | $850.00 | 2 |
| , M.D | Allergy | Medford, OR | $789.17 | 5 |
| , MD | Pulmonary Disease | Andalusia, AL | $766.00 | 7 |
| , M.D | Pulmonary Disease | Rockville, MD | $750.00 | 1 |
| , M.D | Allergy & Immunology | Melrose Park, IL | $736.27 | 7 |
| , MD | Family Medicine | Shelby, NC | $699.91 | 7 |
| , M.D | Internal Medicine | Livonia, MI | $678.69 | 6 |
| , M.D | Internal Medicine | Richardson, TX | $633.99 | 4 |
| , MD | Specialist | Winter Park, FL | $621.24 | 4 |
| , M.D | Allergy & Immunology | Saint Louis, MO | $569.09 | 5 |
| , M.D | Medical Laboratory | San Marcos, CA | $564.95 | 1 |
| , MD | Otolaryngology | New Orleans, LA | $562.25 | 5 |
| , M.D | Pulmonary Disease | Minneapolis, MN | $559.04 | 5 |
| , DO | Pulmonary Disease | Boulder, CO | $530.08 | 4 |
| , M.D | Pulmonary Disease | Charlotte, NC | $208.26 | 3 |
| , MD, MPH | Family Medicine | Houston, TX | $179.30 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 18
- Transactions 173
About QBW251
QBW251 is a drug associated with $3.6M in payments to 18 healthcare providers, recorded across 173 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $2.4M was paid across 44 transactions to 0 doctors.
The most common payment nature for QBW251 is "Unspecified" ($3.6M, 99.7% of total).
QBW251 is associated with 4 research studies, including "A 24 WEEK MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORAL QBW251 IN COPD PATIENTS ON TRIPLE THERAPY (LABA/LAMA/ICS)" ($2.8M).